Cucchetti A, Trevisani F, Bucci L, Ravaioli M, Farinati F, Giannini E G, Ciccarese F, Piscaglia F, Rapaccini G L, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi F G, Missale G, Masotto A, Affronti A, Bernardi M, Pinna A D
Bologna, Italy.
Padova, Italy.
Aliment Pharmacol Ther. 2016 Apr;43(7):814-24. doi: 10.1111/apt.13554. Epub 2016 Feb 11.
Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved.
To assess how many years of life are lost after HCC diagnosis.
Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-onset-matched population derived from national life tables.
Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost for each patient. The youngest age-quartile group (18-61 years) had the highest number of years-of-life lost, representing approximately 41% of the overall benefit obtainable from prevention. Advancements in HCC management have progressively reduced the number of years-of-life lost from 12.6 years in 1986-1999, to 10.7 in 2000-2006 and 7.4 years in 2007-2014. Currently, an HCC diagnosis when a single tumour <2 cm results in 3.7 years-of-life lost while the diagnosis when a single tumour ≥ 2 cm or 2/3 nodules still within the Milan criteria, results in 5.0 years-of-life lost, representing the loss of only approximately 5.5% and 7.2%, respectively, of the entire lifespan from birth.
Hepatocellular carcinoma occurrence results in the loss of a considerable number of years-of-life, especially for younger patients. In recent years, the increased possibility of effectively treating this tumour has improved life expectancy, thus reducing years-of-life lost.
肝细胞癌（HCC）在全球范围内导致过早死亡和预期寿命损失。其一级和二级预防可挽救大量生命年。
评估HCC诊断后损失的生命年数。
使用来自5346例首次诊断为HCC患者的数据，采用半参数外推法估计肿瘤发生后患者的寿命和生命损失年数，以根据国家生命表得出的年龄、性别和发病年份匹配的人群作为参考。
1986年至2014年期间，HCC导致每位患者平均损失11.5个生命年。最年轻的四分位数年龄组（18 - 61岁）生命损失年数最多，约占预防可获得的总体益处的41%。HCC治疗的进展已使生命损失年数逐步减少，从1986 - 1999年的12.6年降至2000 - 2006年的10.7年以及2007 - 2014年的7.4年。目前，单个肿瘤<2 cm时诊断为HCC导致3.7个生命年损失，而单个肿瘤≥2 cm或2/3个结节仍符合米兰标准时诊断为HCC导致5.0个生命年损失，分别仅占出生后整个寿命的约5.5%和7.2%。
肝细胞癌的发生导致大量生命年损失，尤其是对年轻患者而言。近年来，有效治疗该肿瘤可能性的增加提高了预期寿命，从而减少了生命损失年数。
